Table of Contents

Table of Contents ---------- i-vi

List of Tables ---------- vii-x

List of Figures ---------- xi-xiv

Abbreviations ---------- xv-xvii

Chapter I: Introduction ---------- 1-7

I.1 Introduction 1
I.2 Aim And Objectives 7

Chapter II: Literature Review ---------- 8-129

II.1 Introduction 8
II.2 Regional Differences in Drug Absorption 10
II.3 Models for the investigation of intestinal drug absorption and absorption sites 11
II.3.1 In-silico methods 12
II.3.2 In-vitro Methods 12
II.3.2.1 Excised tissue 12
II.3.2.1.1 Perfused intestinal segments 12
II.3.2.1.2 Everted sacs 13
II.3.2.1.3 Intestinal mucosa (stripped/Unstripped) mounted in Ussing chamber 13
II.3.2.2 Isolated enterocytes 14
II.3.2.3 Membrane vesicles (BBMV, BLMV) 15
II.3.2.4 Artificial membrane methods 15
II.3.2.4.1 IAM -Immobilized Artificial Membrane columns 15
II.3.2.4.2 PAMPA- Parallel Artificial Membrane Permeability Assay 16
II.3.3 In-situ intestinal perfusion 18
II.3.4 In Vivo Methods 23
II.3.4.1 Animals 23
II.3.4.2 Humans 24
II.4 Sources of Regional Differences in Drug Absorption 25
II.4.1 Passive diffusion 25
II.4.2 Paracellular absorption 26
II.4.3 Active transport processes 26
II.5 Consequences for Dosage Form Design 27
II.6 Gastrointestinal Transit 28
II.7 Gastro-Retention 28
II.7.1 Pharmacokinetic aspects 30
II.7.1.1 Enhanced bioavailability 30
II.7.1.2 Enhanced first pass biotransformation 30
II.7.1.3 Improved bioavailability due to reduced P-glycoprotein (P-gp) activity in the duodenum 30
II.7.1.4 Reduced frequency of dosing 31
II.7.1.5 Targeted therapy for local ailments in the upper GI tract 31
II.7.2 Pharmacodynamic aspects 31
II.7.2.1 Reduced fluctuations of drug concentration 31
II.7.2.2 Improved selectivity in receptor activation 31

Table of Contents

II.7.2.3 Reduced counter-activity of the body 31
II.7.2.4 Extended time over critical (effective) concentration 31
II.7.2.5 Minimized adverse activity at the colon 32
II.8 Aim of the Thesis 33
II.9 Prior Art 35
II.10 Alfuzosin Hydrochloride 36
II.10.1 Description 36
II.10.2 Empirical formula 36
II.10.3 Chemical structure 37
II.10.4 Physicochemical Properties 37
II.10.5 Pharmacokinetics 37
II.10.5.1 Absorption 37
II.10.5.2 Distribution 37
II.10.5.3 Metabolism 38
II.10.5.4 Elimination 38
II.10.6 Clinical Pharmacology 38
II.10.6.1 Pharmacodynamics 38
II.10.6.2 Adverse Reaction 38
II.10.6.3 Indications and Usage 39
II.10.6.4 Dosage and Administration 39
II.11 Advantages of ER Vs IR 39
II.12 BPH 39
II.12.1 Pathogenesis of BPH 40
II.12.2 Clinical Presentation 41
II.12.3 Tests Used to Diagnose BPH 42
II.12.4 Therapeutic Options 42
II.12.5 Drugs Used to Treat BPH 44
II.13 Commercial Status of Gastric retention Technologies 45
II.14 Patterns of gastric emptying 49
II.15 Factors Influencing Gastric Emptying 50
II.16 Methods Used To Study Gastric Emptying 54
II.17 Effect of food on drug absorption 58
II.17.1 Increased or Accelerated Absorption 59
II.17.1.1 Increased solubility 59
II.17.1.1.1 Due to increased GI Transit Time 59
II.12.1.1.1.1 Inhibitory effects due to 59
II.17.1.1.2 Bile induced solubilization 61
II.17.1.1.3 Increased Secretions 62
II.17.1.1.4 pH 62
II.17.2 Decreased first pass Metabolism 62
II.17.3 Physiological responses 64
II.17.4 Formulation Factors 64
II.17.5 Meal Effects on Drug Diffusivity 65
II.17.6 Other examples of combined effect 66
II.17.7 Other factors which may be responsible are: 68
II.17.7.1 Mixing Contractions (Segmentation Contractions) 68
II.17.7.2 Peristalsis in the Small Intestine 69
II.17.7.3 Control of Peristalsis by Nervous and Hormonal Signals 69
II.18 Design of Gastro retentive Dosage forms 70
II.18.1 Size exclusion method 70
II.18.1.1 Unfoldable, Extendible, or Expandable Systems 71
II.18.1.1.1 Systems unfolding in the stomach 71
II.18.1.1.2 Systems extending to Complex geometric shapes 72
II.18.1.1.3 Systems expanding to larger Sizes 73
II.18.1.2 Superporous Biodegradable Hydrogel Systems 74
II.18.1.2.1 Hydrogels and superporous Hydrogels 75

II.18.1.2.1.1 Conventional Hydrogels 75
II.18.1.2.1.2 Superporous Hydrogels 75
II.18.1.2.1.2.1 Superporous Hydrogel Systems 76
II.18.2 Intragastric Floating Systems (Low Density systems) 83
II.18.2.1 Hydrodynamically Balanced System (HBS) 83
II.18.2.2 Gas-Generating Floating systems 84
II.18.2.3 Volatile Liquid / Vacuum Containing Systems 86
II.18.2.3.1 Intragastric Floating Gastrointestinal Drug Delivery System 86
II.18.2.3.2 Inflatable Gastrointestinal Delivery Systems 87
II.18.2.3.3 Intragastric Osmotically Controlled Drug Delivery System 87
II.18.2.3.4 Low- Density Core Systems 88
II.18.3 High-Density Systems 99
II.18.4 Mucoadhesive Systems 100
II.18.5 Magnetic Systems 104
REFERENCES 106

Chapter III: Analytical Method----------130-141

III.1 Test procedure for assay of Alfuzosin HCL in Alfuzosin ER tablets (10 mg) (By HPLC)130
III.2 Test procedure for content uniformity of Alfuzosin HCL in Alfuzosin ER tablets (10 mg) (By HPLC) 133
III.3 Test procedure for dissolution of Alfuzosin HCL in Alfuzosin ER tablets (10 mg) (By HPLC) 135
III.4 Test procedure for content related substances of Alfuzosin HCL in Alfuzosin ER tablets (10 mg) (By HPLC) 138

Chapter IV: Preformulation----------142-197

IV.1 INTRODUCTION 142
IV.2 MATERIALS & METHOD 142
IV.2.1 Active Pharmaceutical Ingredient Characterization 142
IV.2.1.1 Description 142
IV.2.1.2 Solubility 142
IV.2.1.3 Hygroscopicity (Moisture sensitivity) 142
IV.2.1.4 Density 142
IV.2.1.4.1 Bulk Density (pb) 142
IV.2.1.4.2 Tap density (pt) 143
IV.2.1.5 Compressibility Index 143
IV.2.1.6 Particle Size and Shape Analysis 143
IV.2.1.7 Impurities in Alfuzosin Hydrochloride 143
IV.2.1.8 Thermal analysis 143
IV.2.1.9 FT-IR study 144
IV.2.1.10 X-ray powder diffraction 144
IV.2.2 Drug –Excipients compatibility Study 144
IV.2.3 Dissolution profile of Marketed preparation 146
IV.2.4 Permeability study in rat intestine 146
IV.2.4.1 Animals 146
IV.2.4.2 Perfusion Solution 146
IV.2.4.3 Drug Solution 147
IV.2.4.4 Single-pass Intestinal Perfusion (SPIP) Technique in rats 147
IV.2.4.4.1 Net Water Flux (NWF) Determination 148
IV.2.4.4.2 Drug Permeability Determination 149
IV.2.4.5 Close intestinal loop method in rats 150
IV.2.5 Analytical Methods 151
IV.3 RESULTS 152

IV.3.1 Description 152
IV.3.2 Active Pharmaceutical Characterization 152
IV.3.2.1 Solubility 152
IV.3.2.2 Hygroscopicity (Moisture sensitivity) 153
IV.3.2.3 Bulk Density and Tap Density 153
IV.3.2.4 Compressibility Index 153
IV.3.2.5 Particle Size and Shape Analysis 154
IV.3.2.6 Impurities in Alfuzosin Hydrochloride API 154
IV.3.2.7 Thermal analysis 155
IV.3.2.8 FT-IR study 155
IV.3.2.9 X-ray powder diffraction 156
IV.3.2.10 TGA 158
IV.3.3 Drug –Excipients compatibility Study 159
IV.3.4 Dissolution profile of Marketed preparation 162
IV.3.5 Permeability study in rat intestine 164
IV.3.5.1 Single-pass Intestinal Perfusion (SPIP) Technique in rats 164
IV.3.5.1.1 Net Water Flux (NWF) Determination 164
IV.3.5.1.2 Drug Permeability Determination 164
IV.3.5.2 Closed intestinal loop method in rats 169
IV.4 DISCUSSION 173
IV.5 CONCLUSION 188
REFERENCES 192

Chapter V: Size Exclusion Technology (Non- Swelling) ----------198-250

V.1 INTRODUCTION 198
V.2 MATERIALS 199
V.3 METHOD 200
V.3.1 Approach IA 201
V.3.1.1 Preparation of tablet 201
V.3.1.1.1 Core tablet 201
V.3.1.1.2 Coated tablet 201
V.3.1.2 Evaluation of formulations 201
V.3.1.2.1 Effect of different ratios of polymers 201
V.3.1.2.2 Effect of Magnesium Stearate vs Colloidal silicon dioxide (Syloid 244) as antisticking agent in coating composition 202
V.3.1.2.3 Compatibility of magnesium stearate and colloidal silicon dioxide with Eudragit RSPO and RLPO with DSC 202
V.3.1.2.4 Evaluation of Core Tablet and Polymer coated Tablets 202
V.3.2 Approach IB 203
V.3.2.1 Preparation of tablet 203
V.3.2.1.1 Core Dummy tablet 203
V.3.2.1.2 Seal Coat 203
V.3.2.1.3 Drug Coat 203
V.3.2.1.4 Polymer Coat 203
V.3.2.2 Evaluation of formulations 204
V.3.2.2.1 Effect of different percentage of polymer coating 204
V.3.2.2.2 Evaluation of Finished formulation 204
V.4 Gastric Residence Time 205
V.4.1 Preparation of Barium Sulphate tablets 205
V.4.2 Protocol of the Gastric Residence Time study 205
V.5 Bio Study 210
V.6 Bio-Analytical Method For Estimation Of Alfuzosin In Human Plasma 211
V.7 Development Of Bio Relevant Discriminatory Media 211
V.8 RESULTS 212

Table of Contents

V.8.1 Results of Approach IA 212
V.8.1.1 Effect of different Ratios of polymers 212
V.8.1.2 Effect of Magnesium Stearate used as antisticking agent in coating composition in various media in B.No.15 214
V.8.1.3 With and Without Magnesium Stearate (B.No 15 vs B.No 17) 215
V.8.1.4 Effect of Colloidal silicon dioxide used as antisticking agent in coating composition in various media B.No. 23 216
V.8.1.5 Summary of the DSC endothermic (-) peaks obtained with different samples 218
V.8.1.6 Evaluation of Tablet 224
V.8.1.6.1 Evaluation of Core Tablet 224
V.8.1.6.2 Evaluation of Polymer Coated Tablet 224
V.8.2 Results of Approach IB 225
V.8.2.1 Formulation Composition with Approach IB 225
V.8.2.2 Effect of different % coating with 95:5 (1.13 % vs 2.1%) 226
V.8.2.2.1 Evaluation of Core Dummy Tablet 226
V.8.2.2.2 Evaluation of Drug Coated Tablet 227
V.8.2.2.3 Evaluation of Polymer Coated Tablet 227
V.8.3 Gastric Retention time 230
V.8.4 Bio Results 236
V.8.5 Post Bio IVIVC 238
V.9 DISCUSSION 241
V.10 CONCLUSION 247
REFERENCES 249

Chapter VI: Floating Drug Delivery ---------- 251-273

VI.1 INTRODUCTION 251
VI.2 MATERIAL 253
VI.3 METHOD 254
VI.3.1 Selection of Excipients and Process 254
VI.3.2 Procedure for Tablet preparation 255
VI.3.3 Process and formulation optimization 256
VI.3.4 Gastric Residence Time 256
VI.4 RESULTS 257
VI.5 DISCUSSION 269
VI.6 CONCLUSION 271
REFERENCES 272

Chapter VII: Size Exclusion Technology (Swelling) ---------- 274-354

VII.1 INTRODUCTION 274
VII.2 MATERIALS 281
VII.3 APPROACHES 282
VII.3.1 With PEO + HPMC 282
VII.3.1.1 METHOD 282
VII.3.1.1.1 Formulation with PEO alone (High viscosity grade) 282
VII.3.1.1.2 Formulation with PEO and HPMC combination 282
VII.3.1.1.3 Evaluation of Compressed formulations 283
VII.3.1.1.4 Gastric Residence Time 283
VII.3.1.1.4.1 Preparation of Barium Sulphate tablets 283
VII.3.1.1.4.2 In vitro Evaluation of Tablet containing Barium Sulphate 283
VII.3.1.1.4.3 In vivo Evaluation of Tablet containing Barium Sulphate 283
VII.3.1.1.5 Bio Study 284

Table of Contents

VII.3.1.1.6 Development of Biorelevant Discriminatory media 284
VII.3.1.2 RESULTS 285
VII.3.1.2.1 Formulation with PEO alone (High viscosity grade) 285
VII.3.1.2.2 Formulation with Combination of HPMC and PEO 286
VII.3.1.2.2.1 Evaluation of Compressed formulations 287
VII.3.1.2.2.2 Gastric Residence Time 289
VII.3.1.2.2.2.1 In vitro Evaluation of Tablet containing Barium Sulphate ... 289
VII.3.1.2.2.2.2 In vivo Evaluation of Tablet containing Barium Sulphate ... 289
VII.3.1.2.2.3 Bio Study 296
VII.3.1.2.2.3.1 Statistical Evaluation of B. No 16 (Fed State) 296
VII.3.1.2.2.3.2 Statistical Evaluation of B. No 47 (Fasted State) 300
VII.3.1.2.2.3.3 Statistical Evaluation of B. No 47 (Fed) 303
VII.3.1.2.2.4 Development of Biorelevant Discriminatory media 307
VII.3.1.3 DISCUSSION 314
VII.3.2 With PVP and HPMC combination 321
VII.3.2.1 METHODS 321
VII.3.2.1.1 Evaluation of Compressed formulations 323
VII.3.2.1.2 Bio Study 323
VII.3.2.1.3 IVIVC 323
VII.3.2.1.4 Process Optimization 323
VII.3.2.1.5 Stability study 323
VII.3.2.2 RESULTS 324
VII.3.2.2.1 Evaluation of Compressed formulations 324
VII.3.2.2.2 Bio Study 327
VII.3.2.2.2.1 Statistical Evaluation of B.No 147 (Fasted State) 327
VII.3.2.2.2.2 Statistical Evaluation of B.No 147 (Fed State) 331
VII.3.2.2.2.3 Statistical Evaluation of B.No 158 (Fasted State) 334
VII.3.2.2.2.4 Statistical Evaluation of B.No 158 (Fed State) 337
VII.3.2.2.3 IVIVC 340
VII.3.2.2.4 Process Optimization 341
VII.3.2.2.4.1 Dry mixing 341
VII.3.2.2.4.2 Drying 341
VII.3.2.2.4.2.1 Drying Temperature 342
VII.3.2.2.4.2.2 Drying Time 342
VII.3.2.2.4.3 Tablet Hardness and content uniformity of tablets at different stages of compression 342
VII.3.2.2.4.3.1 Tablet hardness 342
VII.3.2.2.4.3.2 Content uniformity 343
VII.3.2.2.5 Stability study 343
VII.3.2.3 DISCUSSION 345
VII.3.2.4 CONCLUSION 352
REFERENCES 353

Chapter VIII: Summary & Conclusion----------355-356